Kimball Electronics is trying to escape “commodity EMS” valuation by transforming into a higher-moat Medical CMO—success hinges on filling Indianapolis capacity fast enough to unlock margin and multiple expansion.
Overview
Kimball Electronics (KE) is entering late 2025 in the middle of a strategic “reset” designed to transform the company from a commoditized Tier 2 EMS provider into a more defensible, higher-margin Medical CMO. The transition has been messy but intentional: FY2025 revenue fell to ~$1.49B (down ~13.3% YoY) due to a mix of strategic pruning (AT&M divestiture), program churn (a ~$60M automotive braking program reaching end-of-life), and an exogenous shock (a ~$100M medical recall-related headwind tied to a key customer, not blamed on Kimball). Despite the top-line compression, Kimball protected margins, optimized working capital, generated record operating cash flow, and nearly halved debt—materially de-risking the next phase of investment. The growth engine is the newly leased 308k sq. ft. Indianapolis “Kimball Solutions” site, purpose-built for regulated medical manufacturing (cleanrooms, scientific molding, cold chain), aimed at stickier drug-delivery and life-sciences programs. The market, however, continues to value KE like a stagnant manufacturer (~0.6x EV/Revenue, ~8.9x EV/EBITDA), reflecting skepticism that management can fill new capacity and restore organic growth. The bull case is a medical-driven re-rating and margin expansion toward 5%–6%+ operating margins; the bear case is execution failure, customer concentration, and tariff exposure tied to Mexico.